In new final draft guidance, reimbursement authority NICE has recommended that Blenrep (belantamab mafodotin) can be used in ...

Bristol Myers Squibb has tapped up Faro to use AI to improve the Big Pharma's clinical trial protocols. The multi-year agreement will allow BMS to scale AI-powered workflows across trial design, ...

Ann Mongan, director of translational research at BMS, outlines how biomarkers hold pivotal roles in clinical trials.

Oaktree Electrical offers integrated energy-efficient and safe solutions, all backed up by multiple accreditations from national providers.

Tesla owners with 200,000 to 554,000 miles reveal the charging habits that kept their original batteries alive, and one ...

Multiple Myeloma, a cancer of the plasma cells in the bone marrow, is the third most common blood cancer in Europe. Despite ...

Saqib Islam, chief executive Officer of newly launched Beeline Medicines. The pace of private financing in biopharma steps up ...

Foundation Medicine, Inc., a global precision medicine company, today announced an expansion to its collaboration with Bristol Myers Squibb (NYSE: BMY) to develop FoundationOne(R) CDx as a ...

A University of Calgary study led by members of the Arnie Charbonneau Cancer Institute, published in Nature Medicine, takes a ...

A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma, according to results from ...

Dublin, April 13, 2026 (GLOBE NEWSWIRE)-- The "Multiple Sclerosis - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. The report offers comprehensive insights on over ...

All 20 smoldering myeloma patients had deep responses after one-time infusion ...